Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review

Henrique Pereira Sampaio, Barbara Casarin Henrique-Sanches, Carlos Antonio Negrato · 2026

Read Effects of SGLT2 inhibitors on gout-related and cardiometabolic outcomes in patients with type 2 diabetes mellitus: a scoping review by Henrique Pereira Sampaio, Barbara Casarin Henrique-Sanches, Carlos Antonio Negrato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13632354.txt.

Description

Henrique Pereira Sampaio and two colleagues published this 2026 scoping review of a diabetes drug class and gout. The drugs, called SGLT2 inhibitors, lower blood sugar by pushing glucose out through urine. The team searched six databases plus gray sources for studies of patients who had both type 2 diabetes and gout. They tracked uric acid levels, gout flares, emergency visits, hospital stays, and deaths.

Twenty-two studies qualified, mostly backward-looking cohort studies and extra analyses of trials. Only three studied patients with both conditions alone. Across the rest, the drugs were often tied to lower uric acid, fewer new gout cases and flares, and less need to start gout medicines. Several studies also reported lower overall and cardiovascular deaths. The authors call the pattern promising while stressing how few studies target this exact group.

Catalog record

CREATORHenrique Pereira Sampaio, Barbara Casarin Henrique-Sanches, Carlos Antonio Negrato
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE45767
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13632354

Browse the full library · About the Tower of Babel